Engineered immune cells take on recurrent head and neck cancer

NCT ID NCT06096038

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times

Summary

This study tests a new treatment called iC9.CAR-CSPG4 T cells for people with head and neck cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dose and to see how well the body tolerates it. About 33 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.